dc.contributor.author | Onyango-Ouma, W | |
dc.contributor.author | Birungi, H. | |
dc.contributor.author | Geibel., S | |
dc.date.accessioned | 2013-06-29T10:30:36Z | |
dc.date.available | 2013-06-29T10:30:36Z | |
dc.date.issued | 2005 | |
dc.identifier.uri | http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/42348 | |
dc.description.abstract | Background
Improving access to paediatric HIV treatment requires large-scale antiretroviral treatment
programmes and medication adapted to infants and children’s needs. The World Health
Organisation recommends lopinavir/ritonavir plus two nucleoside reverse transcriptase
inhibitors as first-line treatment for all HIV-infected children younger than three years, usually
given as a syrup. A pellet formulation (i.e. tiny cylinders of compressed medication put in
capsules) was developed to overcome the syrup formulation’s disadvantages such as bitterness,
toxicity and cold storage. This study assessed multi-level factors influencing caregivers’
acceptance of and adherence to lopinavir/ritonavir pellets as well as their underlying
mechanisms. | |
dc.language.iso | en | en |
dc.publisher | University of Nairobi | en |
dc.title | Understanding the HIV/STI risks and prevention needs of men who have sex with men in Nairobi, Kenya | en |
dc.type | Article | en |
local.publisher | Institute of African Studies | en |